Researchers at the Stanford University School of Medicine are seeking adults with peanut allergies to participate in clinical trials. The trails are a Phase-1 project to test the tolerability of a vaccine-based treatment intended to lessen allergic responses and a Phase-2 trial to examine an antibody drug aimed at reducing inflammatory response.
"It will be exciting to see what effects these drugs have in food-allergic patients and if it is different compared with oral immunotherapy," says lead investigator Sharon Chinthrajah, MD.
The vaccine is a new type of DNA vaccine intended to desensitize to allergens.
The vaccine works by training the immune system to scale back inflammatory responses to specified allergens. DNA vaccines bring the code for the protein into immune cells rather than exposing the patient to the allergen itself. This is hoped to be a safer alternative for immunotherapy for allergy treatment.
Stanford will be conducting the vaccine trials as one of seven sites around the U.S. in this phase of the testing. The school is in need of adults aged 18 to 55 with a diagnosed peanut allergy.
Atibody treatment testing.
The other trial is for an antibody treatment called ANB020 to assess the efficacy and tolerability of the oral compound. This drug is meant to reduce the immune system's response to allergens like peanut proteins by targeting a particular node in the inflammation response pathway. The idea is that the drug can be used to target more than one allergen type, thus offering a treatment option for several allergies at once.
Stanford is looking for adults aged 18 and older with a diagnosed peanut allergy and no history of life-threatening anaphylactic responses.
More information can be found at ClinicalTrials.gov.